Écrit par GlobalData | 18 Février 2016

LONDON, UK (GlobalData), 18 February 2016 - The treatment market for bipolar disorder is set to decrease from $5.8 billion in 2014 to $4.2 billion by 2024, at a negative Compound Annual Growth Rate (CAGR) of 3.2%, as generic erosion continues to deter the development of novel therapies, according to research and consulting firm GlobalData.

The company’s latest report* states that...

Écrit par Didier Poli | 18 Février 2016

Having successfully completed three studies of non-invasive vagus nerve stimulation (nVNS) for prevention and treatment of cluster headache, electroCore is now expanding its clinical program with two new trials of its gammaCore nVNS therapy in episodic migraine. The first trial is focused on the prevention of migraine, and the second examines the efficacy of nVNS for the acute treatment...

Écrit par PFIZER | 18 Février 2016

Pfizer annonce avoir finalisé l'intégration du vaccin Nimenrix® (vaccin méningococcique conjugué des groupe A, C, W135 et Y. Suite à l’acquisition du vaccin en 2015, il est désormais titulaire de l’AMM et exploitant. Par cette acquisition, Pfizer renforce son portefeuille de vaccins et son engagement dans la prévention des méningites à méningocoques.


« Depuis plus d’un...

Écrit par WHO | 18 Février 2016

SUMMARY


Human-to-human transmission directly linked to the2014 Ebola virus disease (EVD) outbreak in West Africa was declared to haveended in Sierra Leone on 7 November 2015. The country then entered a 90-day periodof enhanced surveillance to ensure the rapid detection of any further casesthat might arise as a result of a missed transmission chain, reintroductionfrom an animal...